The BECN1 Knockout CAL-27 Polyclonal Cells product provides a heterogeneous population of human tongue squamous cell carcinoma (CAL-27) cells in which the BECN1 gene has been disrupted by CRISPR/Cas9-mediated genome editing. This polyclonal knockout population enables loss-of-function studies of Beclin-1, a core autophagy protein, without clonal selection, thereby preserving biological variability inherent to the CAL-27 line. The product is supplied as a ready-to-use polyclonal pool suitable for immediate expansion and functional assays.
CAL-27 is an adherent epithelial cell line derived from a human tongue squamous cell carcinoma and is widely employed as a model system for oral squamous cell carcinoma (OSCC) research. Characterized by TP53 mutation and deregulated PI3K-Akt signaling, CAL-27 cells exhibit aggressive proliferation and are routinely used to investigate OSCC pathogenesis, metastasis, and drug response. The utility of this line is further enhanced by its suitability for xenograft studies and high-throughput screening.
BECN1 encodes Beclin-1, a scaffold protein that nucleates autophagosome formation by assembling the class III PI3K complex. Beclin-1 directly interacts with VPS34, ATG14L, UVRAG, Rubicon, and AMBRA1 to generate PI3P and facilitate LC3 lipidation and p62 degradation. Its activity is regulated by AMPK phosphorylation at Ser93/96, mTOR-mediated inhibition, and BCL-2 binding; DAPK and ULK1 further modulate its function. These interactions place Beclin-1 at the intersection of autophagy and apoptosis signaling.
In the CAL-27 oral cancer context, disruption of BECN1 impairs autophagic flux, leading to accumulation of damaged mitochondria and reactive oxygen species, altered metabolic stress responses, and potential enhancement of tumorigenic properties. Because autophagy can both suppress early tumorigenesis and support advanced tumor survival under metabolic stress, the BECN1 knockout model in CAL-27 is particularly valuable for dissecting context-dependent roles of autophagy in OSCC progression, chemoresistance, and adaptation to hypoxia. Moreover, the polyclonal nature of the knockout cells mimics the genetic heterogeneity observed in patient tumors, making them a relevant tool for preclinical drug testing.
Researchers employ these BECN1 knockout CAL-27 polyclonal cells to investigate autophagy-dependent signaling networks, characterize Beclin-1??s tumor-suppressive functions, and screen autophagy-modulating compounds, including PI3K and mTOR inhibitors. Typical assays performed with this model include Western blotting for LC3 lipidation and p62 turnover, immunofluorescence quantification of LC3 puncta, autophagic flux assays using lysosomal inhibitors such as chloroquine or bafilomycin A1, and functional readouts such as cell viability, apoptosis (Annexin V staining), and wound-healing migration assays. For detailed protocols, batch-specific validation data, or customization requests, please contact Ascent Research.
